This article is more than 5 years old. Information may no longer be current.

Nicox, Re-Vana enter collaboration agreement

Add topic to email alerts

Receive an email when new articles are posted on

Please provide your email address to receive an email when new articles are posted on .

Subscribe

Added to email alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

Back to Healio

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Back to Healio

Nicox and Re-Vana Therapeutics have entered a research collaboration to study the possibility of combining Nicox’s stand-alone nitric oxide donors with Re-Vana’s EyeLief drug delivery platform for the reduction of IOP, according to a Nicox press release.

Re-Vana will be responsible for developing and characterizing EyeLief implants containing the NO donors and for the initial in vitro evaluations of the implants. The development of the EyeLief platform for sustained release of Nicox’s NO donors will be the focus of the nonexclusive agreement, the release said.

“Re-Vana’s technology offers us additional opportunities, alongside our recently announced collaboration with pSivida, to explore the potential for sustained-release delivery of our novel, next generation of stand-alone NO donors,” Michael Bergamini, Nicox executive vice president and chief scientific officer, said in the release. “EyeLief technology has a number of unique properties that have shown promise in the delivery of drugs for the reduction of IOP.”